The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
23-Mar-09
$NA
Target:
BearingPoint, Inc.
Acquiror:
Various
Advised BearingPoint, Inc. on the sale of substantially all of its assets, pursuant to a Section 363 process
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
05-Aug-14
$NA
Target:
Gannett Co., Inc.
Advised Gannett Co., Inc. a media and marketing solutions company, on the spin-off of its Publishing business and the creation of two separate media companies: one focused on television broadcasting and digital marketing and one focused on newspapers.
05-May-22
Undisclosed
Target:
Airtower Networks
Acquiror:
DIF Capital Partners
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
10-Jun-19
$NA
Target:
Book Publishing Business of F+W Media
Acquiror:
Penguin Random House
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the sale of its book publishing business as part of its broader in-court restructuring
13-Aug-12
$32 million
Target:
Journal Communications, Inc.
Advised the Board of Directors of Journal Communications, Inc., a diversified media company with newspaper and broadcasting interests, in connection with the repurchase of 100% of the issued and outstanding shares of its Class C Common Stock from successors to the Company’s founding family
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
29-Nov-18
$86 million
Target:
Wave Computing
Advised Wave Computing, a leading artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on its successful $86mm Series E financing
25-May-17
$115 million
Target:
F+W Media
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the out-of-court restructuring of its c.$100 million term loan and a $15 million new money investment from existing lenders
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
28-Jun-12
$275 million
Target:
Village Roadshow Entertainment Group
Advised Village Roadshow Entertainment Group on its $275 million mezzanine and equity capital raise from a group of investors
18-Jan-22
$321 million
Target:
Fusion Connect, Inc.
Acquiror:
N/A
Advised Fusion Connect, Inc., a leading service provider of cloud communications and secure network solutions with a focus on serving mid-market and enterprise businesses on its comprehensive balance sheet recapitalization
25-Jan-17
$325 million
Target:
Ad Hoc Group of Senior Secured Noteholders
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
13-Dec-11
$345 million
Target:
Cabot Microelectronics Corporation
Advised Cabot Microelectronics Corporation on its new capital management initiative, including a leveraged recapitalization via a special dividend
17-Nov-20
$497 million
Target:
Gannett Co., Inc.
Acquiror:
N/A
Advised Gannett Co., Inc., a news media and marketing solutions company, on the refinancing of ~$500mm of its term loan with convertible notes
03-Feb-20
$650 million
Target:
Clover Wireless
Acquiror:
First Lien Term Loan B Lenders
Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation
11-Mar-21
$725 million
Target:
Speedcast International Limited
Acquiror:
Centerbridge Partners L.P.
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)
14-Jan-20
$760 million
Target:
Fusion Connect, Inc.
Acquiror:
N/A
Advised the Ad Hoc Group of 1L lenders with respect to Fusion's Chapter 11 proceeding
19-Nov-20
$797 million
Target:
iQor Holdings Inc.
Acquiror:
N/A
Advised the ad-hoc Cross-Holder Group of lenders on the fully consensual Prepackaged Plan of Reorganization of iQor Holdings Inc., a business process outsourcing company
11-Dec-12
$862 million
Target:
TNS, Inc.
Acquiror:
Siris Capital Group
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization